UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 12, 2010
GENVEC, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 0-24469 | 23-2705690 |
| (State or other jurisdiction | (Commission | (IRS Employer |
| of Incorporation) | File Number) | Identification No.) |
| 65 West Watkins Mill Road, Gaithersburg, Maryland | 20878 |
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code: | (240) 632 0740 |
| | |
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
INFORMATION TO BE INCLUDED IN THE REPORT
Section 1 – Registrant’s Business and Operations
| Item 1.01 | Entry into a Material Definitive Agreement |
On February 12, 2010, GenVec, Inc. (the “Company”) entered into an agreement with the United States Department of Homeland Security (“DHS”). The agreement provides for payments to the Company of up to $4.55 million over two years, comprised of an initial $3.8 million commitment expected to be realized during the first year of the contract, which runs through January 21, 2011, and an additional $.75 million if DHS exercises its renewal option for an additional year. Under the agreement, the Company will continue the development of prototype adenovector-based vaccines against foot-and-mouth disease with the goals of developing new vaccine candidates and refining the vaccine manufacturing process.
On February 19, 2010, the Company issued a press release announcing the entry into the agreement. A copy of the press release is attached to this current report as Exhibit 99.1 and is incorporated herein by reference.
Section 9 – Financial Statements and Exhibits
| Item 9.01 | Financial Statements and Exhibits |
| Exhibit 99.1 | GenVec, Inc. Press Release issued on February 19, 2010 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | GENVEC, INC. | |
| | | | |
| Date: February 19, 2010 | By: | /s/ DOUGLAS J. SWIRSKY | |
| | | Douglas J. Swirsky | |
| | | Senior Vice President, Chief Financial Officer, Treasurer, and Corporate Secretary | |
| | | | |
EXHIBIT INDEX
| 99.1 | GenVec, Inc. Press Release issued on February 19, 2010 |
